A study in Cell Reports Medicine shows significantly lower NAD+ levels in the brains of Alzheimer’s patients, especially in the parietal and occipital regions. The findings highlight a strong correlation between NAD+ depletion and mitochondrial dysfunction,...
A newly published study reveals that NAD⁺ can restore memory in Alzheimer’s disease models by correcting RNA splicing errors. This groundbreaking international research demonstrates how boosting this essential metabolic molecule improves memory and neuronal function...
NADMED has been selected to join the prestigious AMPlify program, a U.S. market entry initiative jointly organized by Mayo Clinic and Business Finland. The program combines world-class clinical expertise, valuable market knowledge, and extensive networks to support...
Affinity Biomarker Labs, based in London, UK, is the latest partner to join the NADMED network, offering NAD+ and NADH testing upon request. Established in 2017 at Imperial College London’s White City Campus, Affinity Biomarker Labs was founded by a team of clinical...
Research and Markets, one of the world’s leading market research firms, has identified NADMED as one of the fastest-growing clinical laboratory tests in Europe over the next five years. The molecular diagnostics segment, a key area of focus, is projected to achieve a...
The investment round was led by Finnish science-based startup investor Nordic Science Investments (NSI). Additional funding was secured from previous investors Voima Ventures and University of Helsinki Funds, from a number of private European investors, and a grant...
